Download full-text PDF

Source

Publication Analysis

Top Keywords

unquantified benefits
4
benefits problem
4
problem regulation
4
regulation uncertainty
4
unquantified
1
problem
1
regulation
1
uncertainty
1

Similar Publications

Article Synopsis
  • The 2017 guidelines from the American College of Cardiology/American Heart Association identified 31 million US adults with stage 1 hypertension and recommended lifestyle counseling for low-risk patients.
  • A simulation study found that controlling systolic blood pressure in 8.8 million low-risk individuals could significantly reduce cardiovascular events, save lives, and cut healthcare costs over ten years.
  • Despite potential benefits, only half of men and three-quarters of women regularly engage with healthcare providers for counseling, indicating a need for improved public health policies promoting nonpharmacologic interventions.
View Article and Find Full Text PDF
Article Synopsis
  • Multicancer detection (MCD) tests use blood samples to look for multiple types of cancer at the same time, which might help catch cancers earlier, especially those that aren't easy to test for now.* -
  • These tests are different from regular cancer screenings because they don't tell you where the cancer is, so more tests might be needed to figure that out.* -
  • While MCD tests can find some cancers early, their accuracy varies, and there are concerns they might give false negatives, making people less likely to get regular check-ups.*
View Article and Find Full Text PDF

Background: The 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines newly classified 31 million US adults as having stage 1 hypertension. The ACC/AHA guidelines recommend behavioral change without pharmacology for the low-risk portion of this group. However, the nationwide reduction in cardiovascular disease (CVD) and associated healthcare expenditures achievable by evidence-based dietary improvements, sustained weight loss, adequate physical activity, and alcohol moderation remain unquantified.

View Article and Find Full Text PDF

Elective implant removal in the upper extremity: only symptomatic patients benefit.

Eur J Orthop Surg Traumatol

February 2024

Department of Trauma Surgery, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.

Purpose: Elective implant removal (IR) in the upper extremity remains controversial. Implants in the olecranon and clavicle are commonly removed for prominence, unlike in the distal radius. Patient-reported symptomatic cannot be verified, and nonspecific discomfort remains unquantified.

View Article and Find Full Text PDF

The risk-benefit balance of resistance to ionophores in Enterococcus faecium and Enterococcus faecalis for ionophore coccidiostats in broiler chickens.

J Antimicrob Chemother

September 2023

Independent Science, Policy and Regulatory Consultant, Wicklow, Co. Wicklow, Republic of Ireland.

In recent years, publications and debate have emerged in the scientific literature that have linked the use of ionophore coccidiostats, which are themselves not medically important and not related to any therapeutic antibiotics used in human and animal medicine, to resistance development to medically important antibiotics in Enterococcus faecium and Enterococcus faecalis, isolated from broilers and broiler meat. This has been based on the discovery of genes, now named NarAB, that appear to result in elevated MICs of the ionophores narasin, salinomycin and maduramycin and that these are linked to genes responsible for resistance to antibiotics that may be clinically relevant in human medicine. This article will seek to review the most significant publications in this regard and will also examine national antimicrobial resistance surveillance programmes in Norway, Sweden, Denmark and the Netherlands, in order to further evaluate this concern.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!